The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (B...

Full description

Bibliographic Details
Main Authors: Francesco Pantano, Matteo Santoni, Giuseppe Procopio, Mimma Rizzo, Roberto Iacovelli, Camillo Porta, Alessandro Conti, Antonio Lugini, Michele Milella, Luca Galli, Cinzia Ortega, Francesco Maria Guida, Marianna Silletta, Giovanni Schinzari, Elena Verzoni, Daniela Modica, Pierfilippo Crucitti, Annamaria Rauco, Alessandra Felici, Valentina Ballatore, Stefano Cascinu, Giuseppe Tonini, Giacomo Carteni, Antonio Russo, Daniele Santini
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4401714?pdf=render

Internet

http://europepmc.org/articles/PMC4401714?pdf=render

Similar Items